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29.9%) vs 11.3% (11.1%–11.5%), adjusted OR = 2.09 (1.45–
3.02, p < 0.001)], and low HDL [54.5% (46.9%–62.0%) vs
29.4% (29.1%–29.7%), adjusted OR = 2.77 (2.02–3.80, p <
0.001)]. CONCLUSIONS: Compared with the general popula-
tion managed in BSA, MS prevalence was signiﬁcantly higher in
patients with BD, mainly due to higher prevalence of obesity;
high triglycerides and low HDL levels. These ﬁndings strongly
support the development of health policies addressing this health
problem in BD patients.
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OBJECTIVES: To estimate the prevalence of any type Bipolar
Disorder (BP) and comorbidity burden in a Health Management
Organization. METHODS: Cross-sectional assessment of the
Badalona Serveis Assistencials (BSA) administrative claim data-
base. All subjects above 15 years, both sexes, included in BSA
claim database were included in the analysis. Patients with BP,
diagnosed according with DSM-IV criteria formed the study
cohort. The control group was formed for the rest of individu-
als in the BSA database without BD. Prevalence of both BP dis-
order and comorbidities were assessed directly. Corresponding
odds ratios to measure intensity of association were computed
adjusted by age by using logistic regression techniques. The 
following comorbidities groups were assessed: diabetes, hyper-
tension, dyslipidemia, cancer, coronary hearth disease, cere-
brovascular disease, asthma, COPD, obesity, non-dementia
neurological disorders, dementia of any type, and other psychi-
atric disorders. RESULTS: We identiﬁed 178 subjects with BD
(53.4% women, 49.9 + 19.2 years old, mean + SD) out of 86.028
individuals [50,5% women (p = 0.494); 45.5 + 17.8 years (p =
0.001)] in BSA database; overall prevalence = 0.21% (0.18%–
0.24%), men [0.20% (0.17%–0.23%)], women [0.22%
(0.19%–0.25%)]. Patients with BD showed signiﬁcant higher
frequency of dislipidemia [25.8% (95% conﬁdence interval:
19.6%–32.9%) vs 16.2% (15.9%–16.5%); age adjusted OR =
1.54 (1.07–2.23, p = 0.021)], non dementia neurological disor-
ders [2.2% (0.6%–5.7%) vs 0.4% (0.3%–0.4%); adjusted OR
= 4.17 (1.50–11.60, p = 0.006)], dementia [9.0% (5.2%–14.2%)
vs 0.6% (0.5%–0.7%); adjusted OR = 14.00 (7.21–27.21, p <
0.001)], other psychiatric disorder [23.6% (17.6%–30.5%) vs
7.9% (7.7%–8.1%); adjusted OR = 3.29 (2.30–4.70, p < 0.001)]
and obesity [41.4% (32.3%–50.9%) vs 27.1% (26.6%–27.5%);
adjusted OR = 1.83 (1.24–2.68, p = 0.002)]. No other signiﬁ-
cant differences could be found. CONCLUSIONS: The observed
prevalence of Bipolar Disorders was comparable to the one
observed previously in other countries. Compared with general
population managed by BSA, the comorbidity burden is higher
in subjects with Bipolar Disorders, mainly any type neurological
disorders and other psychiatric disorder.
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OBJECTIVES: To correlate changes in negative symptoms of
schizophrenia, assessed by scores on the 16-item Negative
Symptom Assessment scale (NSA-16), with changes in scores on
various functional outcome scales. METHODS: Of 166 stable
outpatients with schizophrenia or schizoaffective disorder par-
ticipating in 1 of 3 medication or psychosocial intervention
studies, 99 had data at baseline and 9 months, and were included
in the analysis. The rating instruments used were the NSA-16,
Brief Psychiatric Rating Scale, and several functional outcome
rating scales: Quality of Life Scale (QLS), Multnomah Commu-
nity Ability Scale (MCAS), Global Assessment of Functioning
(GAF), Social and Occupational Functioning Assessment Scale
(SOFAS), Frontal Systems Behavioral Scale (FrSBe), Functional
Needs Assessment (FNA), and Life Skills Proﬁle (LSP). The asso-
ciation between change scores was assessed using Pearson’s cor-
relation coefﬁcients. RESULTS: Changes in negative symptoms
showed moderate to fairly strong correlations with changes
recorded on all functional outcome rating scales. The associations
were statistically signiﬁcant for all functional outcome measures,
including structured assessments (QLS: r = −0.423, P < 0.0001;
MCAS: r = −0.338, P = 0.0008), global assessments (GAF: r =
−0.521, P < 0.0001; SOFAS: r = −0.497, P < 0.0001), perfor-
mance-based assessments (FrSBe: r = 0.414, P = 0.0003; FNA: 
r = −0.231, P = 0.0247); and observational assessment (LSP: r =
−0.367, P = 0.0003). This pattern of association between reduc-
tions in negative symptoms and improvements in functional
outcome ratings was evident even after controlling for the effects
of treatment-related improvements in positive symptoms. CON-
CLUSIONS: Reductions in negative symptoms, as rated with the
NSA-16, are associated with improvements in clinician- and
patient-assessed functional outcomes measures. This association
is particularly strong when functional outcome is measured on
the QLS, GAF, and SOFAS. These ﬁndings suggest that treatments
that decrease negative symptoms may reduce the considerable
functional disability associated with schizophrenia.
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OBJECTIVES: To present three-months results on treatments
prescribed and their impact on the clinical aspects and Quality
